♥

Bliss GVS Pharma Limited

ISIN : INE416D01022
NSE : BLISSGVS
BSE : 506197
Face Value : 1
Industry : Pharmaceuticals & Drugs

EPS : 7.11
EPS (TTM) : 5.96
Price to Earning (P/E) : 16.57
Book Value : 91.65
Price to Bookvalue (P/B) : 1.29
Dividend Yield : 0 %
Return on Equity (ROE) : 8.89 %
Return on Capital Employed (ROCE) : 12.15 %

Bliss GVS share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	230.8 - 234.3 1.5 %
Low / High	220.7 - 235.6 6.8 %
Trade Volume	1.63 Lk
52 Week Low / High	105.05 - 244.05 132.3 %

YOU MAY ALSO LIKE

Stock market course tutorial
Stock Market Investment Course explained in simple words.
Share Market basics for beginners
Share Market jargons in simple terms
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR BLISS GVS PHARMA LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1886.62	1724.3	2057.17	1847.79	1595.21	2118.77	2007.18	1981.28	1836.43	2176.8
Total Income	1956.72	1745.81	2113.63	1877.57	1646.34	2244.79	2061.41	2037.28	1877.65	2227.17
Total Expenditure	1498.11	1478.85	1580.3	1785.38	1353.08	1575.09	1570.25	1697.81	1493.11	1762.01
Other Income	70.11	21.51	56.46	29.78	51.13	126.02	54.23	56	41.23	50.37
Operating Profit	458.61	266.96	533.33	92.19	293.26	669.7	491.16	339.47	384.54	465.16
Interest	21.14	19.05	12.61	50.84	14.92	14.49	21.18	18.53	15.31	38.26
Exceptional Items								-291.96
PBDT	437.47	247.91	520.72	41.35	278.34	655.21	469.98	28.98	369.23	426.9
Depreciation	45.5	46	46.39	48.84	61.88	63.91	69.54	68.47	68.49	69.82
Profit Before Tax	391.97	201.91	474.33	-7.49	216.46	591.3	400.44	-39.49	300.74	357.08
Tax	117.19	41.89	176.44	-42.16	72.71	160.86	109.72	9.65	79.67	100.14
Profit After Tax	274.78	160.02	297.89	34.67	143.75	430.44	290.72	-49.14	221.07	256.94
Net Profit	274.78	160.02	297.89	34.67	143.75	430.44	290.72	-49.14	221.07	256.94
Equity Capital	103.81	103.89	104.15	104.15	104.22	104.4	104.69	104.69	104.88	105.14
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	2.48	1.33	2.68	0.32	1.41	4.05	2.64	-0.87	1.97	2.31
Diluted Eps After Extraordinary Items	2.44	1.31	2.64	0.33	1.38	3.98	2.6	-0.86	1.93	2.29
Diluted Eps Before Extraordinary Items	2.44	1.31	2.64	0.33	1.38	3.98	2.6	-0.86	1.93	2.29

STANDALONE QUARTERLY RESULT FOR BLISS GVS PHARMA LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1472.8	1388.49	1687.92	1434.19	1089.92	1713.15	1613.35	1638.17	1489.63	1826.46
Total Income	1659.13	1530.8	1802.15	1498.98	1155.19	1819.29	1692.31	1722.81	1558.04	1910
Total Expenditure	1281.32	1122.13	1353.31	1325.08	979.41	1290.07	1326.75	1386.68	1222.21	1572.66
Other Income	186.34	142.31	114.23	64.79	65.27	106.14	78.97	84.64	68.41	83.54
Operating Profit	377.81	408.67	448.84	173.9	175.78	529.22	365.56	336.13	335.83	337.34
Interest	20.42	18.39	12.03	49.73	13.09	11.78	17.88	15.31	11.68	34.48
Exceptional Items								-410.86
PBDT	357.39	390.28	436.81	124.17	162.69	517.44	347.68	-90.04	324.15	302.86
Depreciation	36.74	37.35	37.9	39.74	53.64	56.78	62.48	62.29	62.61	63.95
Profit Before Tax	320.65	352.93	398.91	84.43	109.05	460.66	285.2	-152.33	261.54	238.91
Tax	74.21	98.46	106.11	23.37	34.09	121.75	78.01	-37.72	67.33	68.47
Profit After Tax	246.44	254.47	292.8	61.06	74.96	338.91	207.19	-114.61	194.21	170.44
Net Profit	246.44	254.47	292.8	61.06	74.96	338.91	207.19	-114.61	194.21	170.44
Equity Capital	103.81	103.89	104.15	104.15	104.22	104.4	104.69	104.69	104.88	105.14
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	2.37	2.45	2.81	0.59	0.72	3.25	1.98	-1.09	1.85	1.62
Diluted Eps After Extraordinary Items	2.34	2.41	2.76	0.59	0.71	3.19	1.95	-1.08	1.81	1.62
Diluted Eps Before Extraordinary Items	2.34	2.41	2.76	0.59	0.71	3.19	1.95	-1.08	1.81	1.62

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR BLISS GVS PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	7474.54	7515.88	7702.45
Total Income	7789.46	7693.74	7989.82
Total Expenditure	6291.13	6342.66	6196.21
Other Income	314.92	177.86	287.37
Operating Profit	1498.33	1351.08	1793.61
Interest	47.42	103.64	69.12
Exceptional Items	-735.94		-291.96
PBDT	714.97	1247.44	1432.53
Depreciation	173.31	186.73	263.8
Profit Before Tax	541.66	1060.71	1168.73
Tax	310.39	293.37	352.94
Profit After Tax	231.27	767.34	815.79
Net Profit	231.27	767.34	815.79
Equity Capital	103.68	104.15	104.69
Face Value (IN RS)	1	1	1
Calculated EPS	1.45	6.8	7.21
Diluted Eps After Extraordinary Items	1.43	6.72	7.11
Diluted Eps Before Extraordinary Items	1.43	6.72	7.11

STANDALONE ANNUAL RESULT FOR BLISS GVS PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	6363.57	5983.4	6054.6
Total Income	6689.84	6491.06	6389.6
Total Expenditure	5271.58	5081.85	4982.92
Other Income	326.28	507.66	335.01
Operating Profit	1418.26	1409.21	1406.68
Interest	43.24	100.57	58.06
Exceptional Items	27.45		-410.86
PBDT	1402.47	1308.64	937.76
Depreciation	138.47	151.73	235.19
Profit Before Tax	1264	1156.91	702.57
Tax	337.36	302.14	196.13
Profit After Tax	926.64	854.77	506.44
Net Profit	926.64	854.77	506.44
Equity Capital	103.68	104.15	104.69
Face Value (IN RS)	1	1	1
Calculated EPS	8.94	8.21	4.84
Diluted Eps After Extraordinary Items	8.81	8.1	4.77
Diluted Eps Before Extraordinary Items	8.81	8.1	4.77

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	577.2 Cr	747.45 Cr	751.59 Cr	770.24 Cr
Sales	567.69 Cr	734.27 Cr	746.28 Cr	764.11 Cr
Processing Charges / Service Income	1 Cr	3.66 Cr	1.15 Cr	1.8 Cr
Net Sales	577.2 Cr	747.45 Cr	751.59 Cr	770.24 Cr
Increase/Decrease in Stock	-11.88 Cr	-29.2 Cr	26.94 Cr	-8.35 Cr
Raw Material Consumed	340.78 Cr	420.18 Cr	374.38 Cr	390.46 Cr
Opening Raw Materials	36.63 Cr	45.87 Cr	41.37 Cr	46.85 Cr
Purchases Raw Materials	269.05 Cr	380.78 Cr	335.51 Cr	345.37 Cr
Closing Raw Materials	45.87 Cr	41.37 Cr	46.85 Cr	53.1 Cr
Other Direct Purchases / Brought in cost	80.98 Cr	34.91 Cr	44.34 Cr	51.35 Cr
Power & Fuel Cost	8.14 Cr	8.25 Cr	7.13 Cr	10.43 Cr
Electricity & Power	8.14 Cr	8.25 Cr	7.13 Cr	10.43 Cr
Employee Cost	68.09 Cr	76.15 Cr	86.17 Cr	95.58 Cr
Salaries, Wages & Bonus	52.93 Cr	63.36 Cr	74.61 Cr	83.23 Cr
Contributions to EPF & Pension Funds	2.81 Cr	3.07 Cr	3.52 Cr	4 Cr
Workmen and Staff Welfare Expenses	1.78 Cr	2.93 Cr	3.29 Cr	3.42 Cr
Other Manufacturing Expenses	7.83 Cr	12.09 Cr	12.24 Cr	18.59 Cr
Repairs and Maintenance	7.83 Cr	12.09 Cr	12.24 Cr	18.59 Cr
General and Administration Expenses	12.03 Cr	15.22 Cr	16.5 Cr	17.48 Cr
Rent , Rates & Taxes	1.7 Cr	2.25 Cr	2.54 Cr	2.34 Cr
Insurance	94.04 Lk	1.23 Cr	1.48 Cr	1.63 Cr
Professional and legal fees	4.91 Cr	6.52 Cr	4.5 Cr	5.46 Cr
Traveling and conveyance	3.3 Cr	4.03 Cr	6.57 Cr	6.62 Cr
Selling and Distribution Expenses	31.35 Cr	66.56 Cr	63.95 Cr	68.41 Cr
Advertisement & Sales Promotion	12.22 Cr	26.18 Cr	27.96 Cr	42.15 Cr
Freight and Forwarding	19.13 Cr	40.37 Cr	35.99 Cr	26.25 Cr
Miscellaneous Expenses	14.21 Cr	59.86 Cr	46.96 Cr	28.67 Cr
Bad debts /advances written off	1.55 Cr	16.83 Cr	2.08 Cr	10.51 Cr
Provision for doubtful debts	0	0	13.95 Cr	2.46 Cr
Loss on disposal of fixed assets(net)	3.08 Lk	0	0	0
Total Expenditure	470.56 Cr	629.11 Cr	634.26 Cr	621.27 Cr
Other Income	20.22 Cr	31.49 Cr	17.79 Cr	30.39 Cr
Interest Received	9.58 Cr	8.82 Cr	7.5 Cr	11.79 Cr
Dividend Received	0	0	5,000	0
Profit on sale of Fixed Assets	0	6.83 Lk	36.51 Lk	28.59 Lk
Profits on sale of Investments	0	0	0	17.22 Lk
Foreign Exchange Gains	7.89 Cr	20.06 Cr	7.77 Cr	11.14 Cr
Operating Profit	126.87 Cr	149.83 Cr	135.11 Cr	179.36 Cr
Interest	5.51 Cr	4.74 Cr	10.36 Cr	6.91 Cr
Interest on Term Loan	1.42 Cr	2.39 Cr	2.14 Cr	2.96 Cr
Bank Charges etc	1.21 Cr	1.05 Cr	50.05 Lk	86.1 Lk
PBDT	121.36 Cr	145.09 Cr	124.74 Cr	172.45 Cr
Depreciation	17.23 Cr	17.33 Cr	18.67 Cr	26.38 Cr
Profit Before Taxation & Exceptional Items	104.13 Cr	127.76 Cr	106.07 Cr	146.07 Cr
Exceptional Income / Expenses	0	-73.59 Cr	0	-29.2 Cr
Profit Before Tax	104.13 Cr	54.17 Cr	106.07 Cr	116.87 Cr
Provision for Tax	30.16 Cr	31.04 Cr	29.34 Cr	35.29 Cr
Current Income Tax	26.04 Cr	39.14 Cr	40.75 Cr	32.4 Cr
Deferred Tax	1.23 Cr	-4.74 Cr	-11.51 Cr	2.03 Cr
Profit After Tax	73.97 Cr	23.13 Cr	76.73 Cr	81.58 Cr
Minority Interest	-5.48 Cr	-8.09 Cr	-5.88 Cr	-6.12 Cr
Consolidated Net Profit	68.49 Cr	15.04 Cr	70.86 Cr	75.45 Cr
Profit Balance B/F	673.37 Cr	737.23 Cr	748.72 Cr	814.92 Cr
Appropriations	741.86 Cr	752.27 Cr	819.57 Cr	890.38 Cr
Other Appropriation	4.63 Cr	3.55 Cr	4.65 Cr	3.39 Cr
Equity Dividend %	50	50	50	50
Earnings Per Share	6.64	1.45	6.8	7.21
Adjusted EPS	6.64	1.45	6.8	7.21

STANDALONE PROFIT / LOSS FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	465.51 Cr	636.36 Cr	598.34 Cr	605.46 Cr
Sales	458.25 Cr	624.07 Cr	594.44 Cr	600.18 Cr
Processing Charges / Service Income	1 Cr	3.66 Cr	1.15 Cr	1.8 Cr
Net Sales	465.51 Cr	636.36 Cr	598.34 Cr	605.46 Cr
Increase/Decrease in Stock	-8.85 Cr	-8.9 Cr	21.24 Cr	-6.36 Cr
Raw Material Consumed	262.15 Cr	352.84 Cr	293.66 Cr	305.83 Cr
Opening Raw Materials	30.76 Cr	41.35 Cr	38.41 Cr	42.96 Cr
Purchases Raw Materials	226.25 Cr	347.89 Cr	298.21 Cr	312.7 Cr
Closing Raw Materials	41.35 Cr	38.41 Cr	42.96 Cr	49.83 Cr
Other Direct Purchases / Brought in cost	46.5 Cr	2.01 Cr	0	0
Power & Fuel Cost	6.99 Cr	7.09 Cr	5.8 Cr	8.81 Cr
Electricity & Power	6.99 Cr	7.09 Cr	5.8 Cr	8.81 Cr
Employee Cost	58.61 Cr	65.06 Cr	72.54 Cr	82.59 Cr
Salaries, Wages & Bonus	44.67 Cr	54.14 Cr	62.44 Cr	71.61 Cr
Contributions to EPF & Pension Funds	2.3 Cr	2.62 Cr	3.09 Cr	3.62 Cr
Workmen and Staff Welfare Expenses	1.07 Cr	1.76 Cr	2.34 Cr	2.51 Cr
Other Manufacturing Expenses	7.13 Cr	10.91 Cr	11.09 Cr	17.25 Cr
Repairs and Maintenance	7.13 Cr	10.91 Cr	11.09 Cr	17.25 Cr
General and Administration Expenses	8.7 Cr	12 Cr	10.88 Cr	11.61 Cr
Rent , Rates & Taxes	59.76 Lk	1.25 Cr	1.05 Cr	1.03 Cr
Insurance	62.24 Lk	78.72 Lk	1.03 Cr	1.29 Cr
Professional and legal fees	3.55 Cr	5.86 Cr	3.36 Cr	4.36 Cr
Traveling and conveyance	3.03 Cr	3.17 Cr	4.39 Cr	3.91 Cr
Selling and Distribution Expenses	28.56 Cr	55.7 Cr	56.5 Cr	55.12 Cr
Advertisement & Sales Promotion	11.57 Cr	18.02 Cr	23.54 Cr	32.07 Cr
Freight and Forwarding	16.99 Cr	37.68 Cr	32.96 Cr	23.05 Cr
Miscellaneous Expenses	10.76 Cr	32.45 Cr	36.48 Cr	25.09 Cr
Bad debts /advances written off	1.55 Cr	16.83 Cr	2.08 Cr	10.51 Cr
Provision for doubtful debts	0	0	13.95 Cr	2.46 Cr
Loss on disposal of fixed assets(net)	3.08 Lk	0	0	0
Total Expenditure	374.05 Cr	527.16 Cr	508.18 Cr	499.94 Cr
Other Income	17.68 Cr	32.63 Cr	50.77 Cr	35.15 Cr
Interest Received	10.96 Cr	11.09 Cr	10.15 Cr	13.38 Cr
Dividend Received	0	12.6 Lk	12.6 Lk	12.6 Lk
Profit on sale of Fixed Assets	0	6.83 Lk	36.51 Lk	33.78 Lk
Foreign Exchange Gains	5.69 Cr	19.21 Cr	38.33 Cr	15.16 Cr
Operating Profit	109.14 Cr	141.83 Cr	140.92 Cr	140.67 Cr
Interest	4.19 Cr	4.32 Cr	10.06 Cr	5.81 Cr
Interest on Term Loan	1.19 Cr	1.33 Cr	1.92 Cr	2.9 Cr
Bank Charges etc	1.03 Cr	96.35 Lk	43.24 Lk	74.07 Lk
PBDT	104.95 Cr	137.5 Cr	130.86 Cr	134.86 Cr
Depreciation	13.76 Cr	13.85 Cr	15.17 Cr	23.52 Cr
Profit Before Taxation & Exceptional Items	91.19 Cr	123.66 Cr	115.69 Cr	111.34 Cr
Exceptional Income / Expenses	0	2.75 Cr	0	-41.09 Cr
Profit Before Tax	91.19 Cr	126.4 Cr	115.69 Cr	70.26 Cr
Provision for Tax	23.69 Cr	33.74 Cr	30.21 Cr	19.61 Cr
Current Income Tax	21.52 Cr	31.92 Cr	34.42 Cr	26.34 Cr
Deferred Tax	1.17 Cr	76.77 Lk	-4.21 Cr	-7.55 Cr
Profit After Tax	67.5 Cr	92.66 Cr	85.48 Cr	50.64 Cr
Consolidated Net Profit	67.5 Cr	92.66 Cr	85.48 Cr	50.64 Cr
Profit Balance B/F	613.36 Cr	676.22 Cr	765.34 Cr	846.18 Cr
Appropriations	680.86 Cr	768.89 Cr	850.81 Cr	896.83 Cr
Other Appropriation	4.63 Cr	3.55 Cr	4.63 Cr	4.25 Cr
Equity Dividend %	50	50	50	50
Earnings Per Share	6.54	8.94	8.21	4.84
Adjusted EPS	6.54	8.94	8.21	4.84

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR BLISS GVS PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	104.13 Cr	127.76 Cr	106.07 Cr	146.07 Cr
Adjustment	46.29 Cr	-31.71 Cr	57.92 Cr	38.19 Cr
Changes In working Capital	-57.89 Cr	73.37 Cr	-85.12 Cr	3.04 Cr
Cash Flow after changes in Working Capital	92.53 Cr	169.42 Cr	78.87 Cr	187.3 Cr
Cash Flow from Operating Activities	63.97 Cr	135.48 Cr	34.31 Cr	152.45 Cr
Cash Flow from Investing Activities	-46.99 Cr	-92.98 Cr	-7.75 Cr	-132.82 Cr
Cash Flow from Financing Activitie	-20.8 Cr	-23.73 Cr	-24.94 Cr	-20.89 Cr
Net Cash Inflow / Outflow	-3.82 Cr	18.78 Cr	1.62 Cr	-1.27 Cr
Opening Cash & Cash Equivalents	15.34 Cr	13.13 Cr	21.99 Cr	25.01 Cr
Effect of Foreign Exchange Fluctuations	1.61 Cr	-9.92 Cr	1.4 Cr	-15.01 Lk
Closing Cash & Cash Equivalent	13.13 Cr	21.99 Cr	25.01 Cr	23.59 Cr

STANDALONE CASH FLOW FOR BLISS GVS PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	91.19 Cr	123.66 Cr	115.69 Cr	111.34 Cr
Adjustment	41.14 Cr	35.1 Cr	41.42 Cr	44.27 Cr
Changes In working Capital	-42.64 Cr	-14.23 Cr	-75.58 Cr	-34.94 Lk
Cash Flow after changes in Working Capital	89.69 Cr	144.52 Cr	81.53 Cr	155.26 Cr
Cash Flow from Operating Activities	66.97 Cr	114.05 Cr	43.81 Cr	125.92 Cr
Cash Flow from Investing Activities	-61.62 Cr	-92.28 Cr	-12.97 Cr	-109.59 Cr
Cash Flow from Financing Activitie	-11.67 Cr	-12.62 Cr	-26.05 Cr	-20.76 Cr
Net Cash Inflow / Outflow	-6.33 Cr	9.14 Cr	4.79 Cr	-4.43 Cr
Opening Cash & Cash Equivalents	11 Cr	4.67 Cr	13.82 Cr	18.6 Cr
Closing Cash & Cash Equivalent	4.67 Cr	13.82 Cr	18.6 Cr	14.17 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Equity - Authorised	15 Cr	15 Cr	15 Cr	15 Cr
Equity - Issued	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Equity Paid Up	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Face Value	1	1	1	1
Total Reserves	788.1 Cr	798.4 Cr	864.59 Cr	949 Cr
Securities Premium	14.76 Cr	21.28 Cr	26.99 Cr	33.16 Cr
Capital Reserves	0	0	0	-72.74 Lk
Profit & Loss Account Balance	737.23 Cr	748.72 Cr	814.92 Cr	886.99 Cr
General Reserves	45.42 Cr	45.42 Cr	45.42 Cr	45.42 Cr
Reserve excluding Revaluation Reserve	788.1 Cr	798.4 Cr	864.59 Cr	949 Cr
Shareholder's Funds	808.25 Cr	818.7 Cr	883.9 Cr	967.19 Cr
Minority Interest	19.66 Cr	27.76 Cr	33.53 Cr	35.79 Cr
Secured Loans	32.6 Cr	23.22 Cr	40.69 Cr	35.59 Cr
Term Loans - Banks	32.6 Cr	23.22 Cr	40.69 Cr	54.89 Cr
Deferred Tax Assets / Liabilities	8.21 Cr	1.32 Cr	-3.33 Cr	3.59 Cr
Deferred Tax Assets	3.59 Cr	13.16 Cr	21.99 Cr	25.59 Cr
Deferred Tax Liability	11.8 Cr	14.48 Cr	18.66 Cr	29.19 Cr
Other Long Term Liabilities	1.93 Cr	3.58 Cr	2.79 Cr	9.34 Cr
Long Term Provisions	2.5 Cr	1.07 Cr	2.69 Cr	2.54 Cr
Total Non-Current Liabilities	45.24 Cr	29.2 Cr	42.84 Cr	51.06 Cr
Trade Payables	74.22 Cr	92.61 Cr	86.39 Cr	60.97 Cr
Sundry Creditors	74.22 Cr	92.61 Cr	86.39 Cr	60.97 Cr
Other Current Liabilities	53.69 Cr	67.85 Cr	54.86 Cr	64.87 Cr
Advances received from customers	15.79 Cr	8.73 Cr	3.15 Cr	6.58 Cr
Interest Accrued But Not Due	31.69 Lk	15.9 Lk	6.21 Lk	11.5 Lk
Short Term Borrowings	65.04 Cr	60.7 Cr	46.01 Cr	32.12 Cr
Secured ST Loans repayable on Demands	65.04 Cr	45.09 Cr	30.67 Cr	26.96 Cr
Working Capital Loans- Sec	65.04 Cr	45.09 Cr	30.67 Cr	26.96 Cr
Short Term Provisions	10.69 Cr	11.93 Cr	6 Cr	1.87 Cr
Provision for Tax	8.6 Cr	6.65 Cr	2.66 Cr	1.87 Cr
Total Current Liabilities	203.64 Cr	233.09 Cr	193.26 Cr	159.82 Cr
Total Liabilities	1076.79 Cr	1108.75 Cr	1153.52 Cr	1213.87 Cr
Gross Block	285.1 Cr	343.41 Cr	458.74 Cr	467.78 Cr
Less: Accumulated Depreciation	51.38 Cr	62.65 Cr	80.69 Cr	98.41 Cr
Net Block	233.72 Cr	280.76 Cr	378.05 Cr	369.37 Cr
Capital Work in Progress	2.39 Cr	22.15 Cr	2.8 Cr	7.83 Cr
Non Current Investments	69.93 Lk	3.08 Cr	2.84 Cr	3.61 Cr
Long Term Investment	69.93 Lk	3.08 Cr	2.84 Cr	3.61 Cr
Quoted	0	2.15 Cr	51.12 Lk	0
Unquoted	69.93 Lk	92.27 Lk	2.33 Cr	3.61 Cr
Long Term Loans & Advances	12.62 Cr	25.25 Cr	17.62 Cr	16.25 Cr
Other Non Current Assets	62.15 Cr	1.47 Cr	54.16 Cr	4.5 Cr
Total Non-Current Assets	311.59 Cr	332.71 Cr	456.15 Cr	402.25 Cr
Currents Investments	0	0	4.96 Cr	55.73 Lk
Quoted	0	0	4.96 Cr	55.73 Lk
Unquoted	69.93 Lk	92.27 Lk	2.33 Cr	3.61 Cr
Inventories	98.93 Cr	123.94 Cr	103.06 Cr	118.45 Cr
Raw Materials	45.87 Cr	41.37 Cr	46.85 Cr	53.1 Cr
Work-in Progress	3.34 Cr	8.23 Cr	4.44 Cr	6.3 Cr
Finished Goods	31.54 Cr	34.59 Cr	17.57 Cr	21.86 Cr
Packing Materials	14.36 Cr	14.8 Cr	14.96 Cr	16.5 Cr
Stores and Spare	2.72 Cr	2.58 Cr	3.01 Cr	2.26 Cr
Sundry Debtors	463.82 Cr	392.75 Cr	385.17 Cr	404.35 Cr
Debtors more than Six months	3.93 Cr	57.53 Cr	66.72 Cr	33.47 Cr
Debtors Others	468.64 Cr	349.89 Cr	353.84 Cr	407.09 Cr
Cash and Bank	144.55 Cr	177.53 Cr	102.98 Cr	215.62 Cr
Cash in hand	11.13 Lk	5.16 Lk	8.53 Lk	6.64 Lk
Balances at Bank	144.44 Cr	177.47 Cr	102.9 Cr	215.55 Cr
Other Current Assets	22.12 Cr	14.12 Cr	6.63 Cr	17.01 Cr
Interest accrued on Investments	6.66 Cr	9.17 Cr	3.4 Cr	10.07 Cr
Deposits with Government	0	0	0	3.29 Cr
Prepaid Expenses	1.43 Cr	3.19 Cr	2.42 Cr	2.78 Cr
Short Term Loans and Advances	35.78 Cr	67.7 Cr	94.56 Cr	55.65 Cr
Advances recoverable in cash or in kind	20.8 Cr	53.62 Cr	51.67 Cr	18.16 Cr
Advance income tax and TDS	1.46 Cr	25.51 Lk	1.62 Cr	2.91 Cr
Total Current Assets	765.2 Cr	776.03 Cr	697.37 Cr	811.62 Cr
Net Current Assets (Including Current Investments)	561.56 Cr	542.95 Cr	504.11 Cr	651.8 Cr
Total Assets	1076.79 Cr	1108.75 Cr	1153.52 Cr	1213.87 Cr
Contingent Liabilities	11.09 Lk	22.7 Cr	11.59 Cr	56.89 Cr
Total Debt	118.75 Cr	104.96 Cr	98.07 Cr	87.81 Cr
Book Value	77.41	78.01	84.01	91.65
Adjusted Book Value	77.41	78.01	84.01	91.65

STANDALONE BALANCE SHEET FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Equity - Authorised	15 Cr	15 Cr	15 Cr	15 Cr
Equity - Issued	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Equity Paid Up	10.31 Cr	10.37 Cr	10.42 Cr	10.47 Cr
Face Value	1	1	1	1
Total Reserves	735.5 Cr	831.12 Cr	917.69 Cr	970.25 Cr
Securities Premium	14.76 Cr	21.28 Cr	26.99 Cr	33.16 Cr
Profit & Loss Account Balance	676.22 Cr	765.34 Cr	846.18 Cr	892.57 Cr
General Reserves	44.51 Cr	44.51 Cr	44.51 Cr	44.51 Cr
Reserve excluding Revaluation Reserve	735.5 Cr	831.12 Cr	917.69 Cr	970.25 Cr
Shareholder's Funds	755.65 Cr	851.43 Cr	937 Cr	988.44 Cr
Secured Loans	32.49 Cr	23.22 Cr	40.69 Cr	35.1 Cr
Term Loans - Banks	32.49 Cr	23.22 Cr	40.69 Cr	54.89 Cr
Deferred Tax Assets / Liabilities	7.05 Cr	7.92 Cr	3.48 Cr	-4.12 Cr
Deferred Tax Assets	3.59 Cr	5.01 Cr	13.64 Cr	24.32 Cr
Deferred Tax Liability	10.64 Cr	12.93 Cr	17.12 Cr	20.21 Cr
Other Long Term Liabilities	1.83 Cr	3.49 Cr	2.56 Cr	9.24 Cr
Long Term Provisions	2.5 Cr	1.07 Cr	2.61 Cr	2.47 Cr
Total Non-Current Liabilities	43.87 Cr	35.71 Cr	49.34 Cr	42.69 Cr
Trade Payables	66.78 Cr	84.21 Cr	75.87 Cr	54.47 Cr
Sundry Creditors	66.78 Cr	84.21 Cr	75.87 Cr	54.47 Cr
Other Current Liabilities	42.36 Cr	62.46 Cr	50.72 Cr	51.57 Cr
Advances received from customers	7.98 Cr	5.67 Cr	1.54 Cr	4.23 Cr
Interest Accrued But Not Due	26.76 Lk	15.9 Lk	5.59 Lk	9.16 Lk
Short Term Borrowings	35.38 Cr	41.47 Cr	25.02 Cr	10.74 Cr
Secured ST Loans repayable on Demands	35.38 Cr	41.47 Cr	25.02 Cr	10.74 Cr
Working Capital Loans- Sec	35.38 Cr	41.47 Cr	25.02 Cr	10.74 Cr
Short Term Provisions	1.59 Cr	4.69 Cr	1.74 Cr	53.71 Lk
Provision for Tax	1.59 Cr	4.69 Cr	1.74 Cr	53.71 Lk
Total Current Liabilities	146.11 Cr	192.83 Cr	153.36 Cr	117.31 Cr
Total Liabilities	945.62 Cr	1079.96 Cr	1139.69 Cr	1148.44 Cr
Gross Block	210.93 Cr	269.54 Cr	385.02 Cr	413.45 Cr
Less: Accumulated Depreciation	36.84 Cr	45.22 Cr	60.21 Cr	83.5 Cr
Net Block	174.1 Cr	224.32 Cr	324.82 Cr	329.95 Cr
Capital Work in Progress	2.39 Cr	22.15 Cr	2.8 Cr	7.83 Cr
Non Current Investments	18.99 Cr	18.94 Cr	18.26 Cr	18.69 Cr
Long Term Investment	18.99 Cr	18.94 Cr	18.26 Cr	18.69 Cr
Unquoted	18.99 Cr	18.94 Cr	18.26 Cr	59.78 Cr
Long Term Loans & Advances	11.35 Cr	23.27 Cr	17.18 Cr	15.8 Cr
Other Non Current Assets	62.15 Cr	36.55 Lk	46.3 Cr	2.5 Cr
Total Non-Current Assets	268.98 Cr	289.05 Cr	410.04 Cr	375.46 Cr
Unquoted	18.99 Cr	18.94 Cr	18.26 Cr	59.78 Cr
Inventories	83.68 Cr	90.11 Cr	74.15 Cr	89.45 Cr
Raw Materials	41.35 Cr	38.41 Cr	42.96 Cr	49.83 Cr
Work-in Progress	2.86 Cr	7.71 Cr	3.65 Cr	5.38 Cr
Finished Goods	26.6 Cr	30.85 Cr	13.67 Cr	18.3 Cr
Packing Materials	9.92 Cr	10.55 Cr	10.85 Cr	13.67 Cr
Stores and Spare	2.72 Cr	2.58 Cr	3.01 Cr	2.26 Cr
Sundry Debtors	348.68 Cr	408.82 Cr	399.06 Cr	399.51 Cr
Debtors more than Six months	3.93 Cr	49.5 Cr	94.86 Cr	45.14 Cr
Debtors Others	353.5 Cr	374 Cr	339.6 Cr	390.58 Cr
Cash and Bank	119.52 Cr	149.48 Cr	84.61 Cr	169.32 Cr
Cash in hand	1.94 Lk	1.27 Lk	2.88 Lk	2.16 Lk
Balances at Bank	119.5 Cr	149.47 Cr	84.58 Cr	169.3 Cr
Other Current Assets	23.28 Cr	16.77 Cr	14.15 Cr	25.74 Cr
Interest accrued on Investments	14.48 Cr	13.74 Cr	11.92 Cr	19.33 Cr
Deposits with Government	0	0	0	3.29 Cr
Prepaid Expenses	1.08 Cr	2.52 Cr	1.94 Cr	2.35 Cr
Short Term Loans and Advances	101.48 Cr	125.72 Cr	157.68 Cr	88.96 Cr
Advances recoverable in cash or in kind	19.73 Cr	32.43 Cr	29.32 Cr	18.02 Cr
Advance income tax and TDS	41.89 Lk	2.04 Lk	1.07 Cr	2.45 Cr
Total Current Assets	676.64 Cr	790.92 Cr	729.65 Cr	772.98 Cr
Net Current Assets (Including Current Investments)	530.54 Cr	598.09 Cr	576.3 Cr	655.67 Cr
Total Assets	945.62 Cr	1079.96 Cr	1139.69 Cr	1148.44 Cr
Contingent Liabilities	30.06 Cr	21.81 Cr	10.09 Cr	55.82 Cr
Total Debt	88.87 Cr	85.61 Cr	77.08 Cr	65.63 Cr
Book Value	72.31	0	89.11	93.68
Adjusted Book Value	72.31	81.16	89.11	93.68

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	6.64	1.45	6.8	7.21
CEPS(Rs)	8.84	3.9	9.16	10.31
DPS(Rs)	0.5	0.5	0.5	0.5
Book NAV/Share(Rs)	77.41	78.01	84.01	91.65
Tax Rate(%)	28.96	57.3	27.66	30.2
Margin Ratios
Core EBITDA Margin(%)	18.48	15.83	15.61	19.34
EBIT Margin(%)	19	7.88	15.49	16.07
Pre Tax Margin(%)	18.04	7.25	14.11	15.17
PAT Margin (%)	12.82	3.09	10.21	10.59
Cash Profit Margin (%)	15.8	5.41	12.69	14.02
Performance Ratios
ROA(%)	7.03	2.12	6.78	6.89
ROE(%)	9.64	2.88	9.11	8.89
ROCE(%)	12.29	6.37	12.22	12.15
Asset Turnover(x)	0.55	0.68	0.66	0.65
Sales/Fixed Asset(x)	2.06	2.38	1.87	1.66
Working Capital/Sales(x)	1.03	1.38	1.49	1.18
Efficiency Ratios
Fixed Capital/Sales(x)	0.49	0.42	0.53	0.6
Receivable days	319.89	209.14	188.89	187.07
Inventory Days	54.72	54.42	55.12	52.48
Payable days	62.91	77.87	81.4	70.38
Valuation Parameters
PER(x)	14.86	53.04	10.47	15.63
PCE(x)	11.16	19.72	7.78	10.92
Price/Book(x)	1.28	0.99	0.85	1.23
Yield(%)	0.51	0.65	0.7	0.44
EV/Net Sales(x)	1.72	0.97	0.98	1.37
EV/Core EBITDA(x)	7.82	4.84	5.46	5.86
EV/EBIT(x)	9.05	12.31	6.33	8.49
EV/CE(x)	0.92	0.65	0.75	1
M Cap / Sales	1.76	1.07	0.99	1.53
Growth Ratio
Net Sales Growth(%)	-16.26	29.5	0.55	2.48
Core EBITDA Growth(%)	-21.93	16.51	-9.83	32.75
EBIT Growth(%)	-19.7	-47.11	97.66	6.31
PAT Growth(%)	-22.34	-68.74	231.81	6.31
EPS Growth(%)	-29.58	-78.15	368.98	5.94
Financial Stability Ratios
Total Debt/Equity(x)	0.15	0.13	0.11	0.09
Current Ratio(x)	3.76	3.33	3.61	5.08
Quick Ratio(x)	3.27	2.8	3.08	4.34
Interest Cover(x)	19.89	12.42	11.23	17.91
Total Debt/Mcap(x)	0.12	0.13	0.13	0.07

FINANCIAL RATIOS (STANDALONE) FOR BLISS GVS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	6.54	8.94	8.21	4.84
CEPS(Rs)	7.88	10.27	9.66	7.08
DPS(Rs)	0.5	0.5	0.5	0.5
Book NAV/Share(Rs)	72.31	81.16	89.11	93.68
Tax Rate(%)	25.98	26.69	26.12	27.92
Margin Ratios
Core EBITDA Margin(%)	19.65	17.16	15.07	17.43
EBIT Margin(%)	20.49	20.54	21.02	12.56
Pre Tax Margin(%)	19.59	19.86	19.34	11.6
PAT Margin (%)	14.5	14.56	14.29	8.36
Cash Profit Margin (%)	17.46	16.74	16.82	12.25
Performance Ratios
ROA(%)	7.5	9.15	7.7	4.43
ROE(%)	9.45	11.68	9.66	5.31
ROCE(%)	11.81	14.68	12.89	7.36
Asset Turnover(x)	0.52	0.63	0.54	0.53
Sales/Fixed Asset(x)	2.25	2.65	1.83	1.52
Working Capital/Sales(x)	0.88	1.06	1.04	0.92
Efficiency Ratios
Fixed Capital/Sales(x)	0.44	0.38	0.55	0.66
Receivable days	295.44	217.24	246.41	240.71
Inventory Days	56.55	49.84	50.1	49.31
Payable days	59.03	80.11	92.78	79.43
Valuation Parameters
PER(x)	15.08	8.61	8.68	23.29
PCE(x)	12.53	7.49	7.37	15.9
Price/Book(x)	1.37	0.95	0.8	1.2
Yield(%)	0.51	0.65	0.7	0.44
EV/Net Sales(x)	2.12	1.15	1.23	1.78
EV/Core EBITDA(x)	9.05	5.17	5.21	7.65
EV/EBIT(x)	10.35	5.61	5.84	14.14
EV/CE(x)	1.04	0.68	0.72	1.02
M Cap / Sales	2.19	1.25	1.24	1.95
Growth Ratio
Net Sales Growth(%)	5.33	36.7	-5.97	1.19
Core EBITDA Growth(%)	-20.43	27.92	-0.64	-0.18
EBIT Growth(%)	-25.68	34.62	-3.81	-39.51
PAT Growth(%)	-26.9	37.28	-7.75	-40.75
EPS Growth(%)	-26.9	36.58	-8.18	-41.06
Financial Stability Ratios
Total Debt/Equity(x)	0.12	0.1	0.08	0.07
Current Ratio(x)	4.63	4.1	4.76	6.59
Quick Ratio(x)	4.06	3.63	4.27	5.83
Interest Cover(x)	22.74	30.23	12.5	13.1
Total Debt/Mcap(x)	0.09	0.11	0.1	0.06

SHARE HOLDING PATTERN FOR BLISS GVS PHARMA LIMITED

Date	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters %	33.14	34.51	34.55	34.46	35.04	35.12	35.06	34.97	34.97	34.90
FII %	17.33	17.17	16.68	16.53	16.60	16.50	16.31	15.36	14.74	13.24
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00
Public %	42.87	41.67	42.13	42.38	41.73	41.75	42.01	43.08	43.71	45.27

PEER COMPARISON FOR BLISS GVS PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR BLISS GVS

Exchange Date	Purpose	Book Closure Dates
BSE 17-Oct-2024	Board Meeting - Quarterly Results	24-Oct-2024
BSE 18-Jul-2024	Board Meeting - Quarterly Results	24-Jul-2024
BSE 06-May-2024	Book Closure - Rs.0.5000 per share(50%)Final Dividend & A.G.M.	19-Jul-2024 25-Jul-2024
BSE 03-May-2024	AGM - Inter alia, approved:- 1. Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company (?39th AGM?); 2. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP Registration No. AAB-7880 as Internal...	25-Jul-2024
BSE 03-May-2024	Dividend - Rs.0.5000 per share(50%)Final Dividend
BSE 26-Apr-2024	Board Meeting - Audited Results & Final Dividend	02-May-2024
BSE 16-Jan-2024	Board Meeting - Quarterly Results	23-Jan-2024
BSE 26-Oct-2023	Board Meeting - Quarterly Results	01-Nov-2023
BSE 24-Jul-2023	Board Meeting - Quarterly Results	01-Aug-2023
BSE 12-May-2023	Book Closure - Rs.0.5000 per share(50%)Final Dividend & A.G.M.	13-Jul-2023 19-Jul-2023
BSE 12-May-2023	AGM - Rs.0.5000 per share(50%)Final Dividend & A.G.M.	19-Jul-2023 19-Jul-2023
BSE 11-May-2023	Dividend - Rs.0.5000 per share(50%)Final Dividend
BSE 04-May-2023	Board Meeting - Audited Results & Final Dividend	11-May-2023
BSE 17-Jan-2023	Board Meeting - Quarterly Results	24-Jan-2023
BSE 31-Oct-2022	Board Meeting - Quarterly Results	07-Nov-2022
BSE 20-Jun-2022	Dividend - Rs.0.5000 per share(50%)Final Dividend
BSE 02-May-2022	Book Closure - Rs.0.5000 per share(50%)Final Dividend & A.G.M.	22-Jun-2022 28-Jun-2022
BSE 02-May-2022	AGM - Rs.0.5000 per share(50%)Final Dividend & A.G.M.	28-Jun-2022 28-Jun-2022
BSE 22-Apr-2022	Board Meeting - Final Dividend & Audited Results	30-Apr-2022
BSE 21-Jan-2022	Board Meeting - Quarterly Results	29-Jan-2022
BSE 22-Oct-2021	Board Meeting - Quarterly Results	30-Oct-2021

CORPORATE ANNOUNCEMENTS FOR BLISS GVS

Exchange Date	Category File	Description
BSE 30-Oct-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Narsimha Shibroor Kamath & PACs
BSE 30-Oct-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Narsimha Shibroor Kamath & PACs
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Enclosed herewith the copies of the newspaper advertisement published regarding the extract of the statement of unaudited standalone and consolidated financial results for the quarter and half year ended September 30 2024.
BSE 24-Oct-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday October 24 2024 Please find the attached Outcome of Board Meeting held on Thursday October 24 2024.
BSE 17-Oct-2024	Intimation FILE	Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Yearly Ended September 30 2024 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024 Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024
BSE 17-Oct-2024	Intimation FILE	Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Yearly Ended September 30 2024 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024
BSE 04-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find enclosed herewith a certificate received from Link Intime Private Limited Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2024.
BSE 04-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS We like to inform you that the ESOP Allotment Committee of the Company at its meeting held on October 04 2024 has approved the allotment of 1 57 550 equity shares of the face value of Re.1/-each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 ("Bliss GVS ESOP-2019").
BSE 30-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of Closure of the Trading Window is attached.
BSE 18-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Enclosed herewith the details of loss of share certificate.
BSE 12-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS We like to inform you that the ESOP Allotment Committee of the Company at its meeting held on September 12 2024 has approved the allotment of 1 14 750 equity shares of the face value of Re.1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma -Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).
BSE 27-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Intimation of Completion of Term of Mr. Subramanian Ramaswamy Vaidya (DIN: 03600249) as an Independent Director of the Company.
BSE 27-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Enclosed herewith the details of loss of share certificates.
BSE 22-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the company has received letters via email from the Stock Exchanges dated August 21 2024 have each imposed a fine on the Company for non-compliance with Regulation 17(1A) of the SEBI Listing Regulations. Please be informed that the Company is actively addressing this issue by applying for a waiver and even appleaing to the appropriate appellate authority if required.
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS We like to inform you that the ESOP Committee of the Company at its meeting held on August 14 2024 has approved the allotment of 64 150 equity shares of the face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 ("Bliss GVS ESOP-2019")
BSE 14-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Enclosed herewith the details of loss of share certificate.
BSE 07-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Enclosed herewith the details of loss of share certificate.
BSE 02-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Enclosed herewith copies of the newspaper advertisement of the notice published in The Free Press Journal (English) and Navshakti (Regional) on August 02 2024 concerning the proposed transfer of unclaimed final dividend 2016-2017 and its corresponding shares to IEPF Authority.
BSE 02-Aug-2024	General Announcements FILE	Notice To Shareholders W.R.T. Transfer Of Unclaimed Final Dividend 2016-2017 And Its Corresponding Shares To Investor Education And Protection Fund (IEPF) Authority Enclosed herewith a copy of the communication sent to those concerned shareholders whose dividends have remained unclaimed for a period of seven consecutive years or more concerning the proposed transfer of unclaimed final dividend 2016-2017 and its corresponding shares to the IEPF Authority.
BSE 30-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed herewith the copies of the newspaper advertisement published regarding the extract of the statement of unaudited standalone and consolidated financial results for the quarter ended June 30 2024 in The Ecconomics Times & The Free Press Journal an English Daily and Maharashtra Times & Navshakti a Regional Daily on June 26 2024.
BSE 26-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that our Registrar and Transfer Agent viz. Link Intime India Private Limited has informed us regarding the loss of share certificates and request for the issue of share certificates from the shareholder.
BSE 25-Jul-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Enclosed herewith the Disclsoure of Voting Results alongwith Scrutinizer Report for the 39th Annual General Meeting held on July 25 2024.
BSE 25-Jul-2024	General Announcements FILE	Proceedings Of The 39Th Annual General Meeting Held On Thursday July 25 2024 Enclosed herewith proceedings of the 39th Annual General Meeting held on Thursday July 25 2024 at 11:00 a.m. through VC/OAVM.
BSE 24-Jul-2024	Outcome FILE	Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2024 Please find attached herewith the Outome of Board Meeting held on today i.e. July 24 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024.
BSE 18-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that our Registrar and Transfer Agent viz. Link Intime India Private Limited has informed us regarding the loss of share certificate and request for the issue of share certificate from the shareholder.
BSE 17-Jul-2024	Intimation FILE	Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2024 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024.Further according to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2024 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2024.
BSE 12-Jul-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find enclosed herewith a certificate received from Link Intime India Private Limited Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2024.
BSE 09-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on July 09 2024 has approved the allotment of 83 000 equity shares of the face value of Re.1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 ("Bliss GVS ESOP-2019").
BSE 05-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed copies of newspaper advertisements pertaining to the Notice of 39th Annual General Meeting of the Company scheduled to be held on Thursday July 25 2024 at 11:00 a.m. (IST) through Video Conferencing/Other Audio-Visual Means e-Voting and Book Closure.
BSE 03-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Please find enclosed the Business Responsibility and Sustainability Report for the financial year 2023-2024 which forms an integral part of the Annual Report for the financial year 2023-2024.

INSIDER TRADING FOR BLISS GVS

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 14-Jun-2023 14-Jun-2023	Buy Market	115,000 @ 0.00 (0.11 %)	Vibha Gagan Sharma
BSE 14-Jun-2023 14-Jun-2023	Buy Market	115,000 @ 0.00 (0.11 %)	Vibha Gagan Sharma
BSE 24-Feb-2023 24-Feb-2023	Buy Market	300,000 @ 0.00 (0.29 %)	Narsimha Shibroor Kamath
BSE 06-Jun-2022 06-Jun-2022	Buy Market	250,000 @ 0.00 (0.24 %)	Vibha Gagan Sharma
BSE 27-May-2022 27-May-2022	Buy Market	130,000 @ 0.00 (0.12 %)	Shruti Vishal Rao
BSE 26-May-2022 27-May-2022	Buy Market	260,000 @ 0.00 (0.25 %)	Vibha Gagan Sharma
BSE 25-May-2022 25-May-2022	Buy Market	130,000 @ 0.00 (0.12 %)	Shruti Vishal Rao
BSE 30-Mar-2022 31-Mar-2022	Buy Market	350,000 @ 0.00 (0.34 %)	Shruti Vishal Rao
BSE 31-Mar-2022 31-Mar-2022	Buy Market	350,000 @ 0.00 (0.34 %)	Vibha Gagan Sharma
BSE 29-Mar-2022 29-Mar-2022	Sell Inter-Se Transfer	3,000,000 @ 0.00 (2.90 %)	Narsimha Shibroor Kamath
BSE 29-Mar-2022 29-Mar-2022	Buy Inter-Se Transfer	1,500,000 @ 0.00 (0.00 %)	Shruti Vishal Rao
BSE 29-Mar-2022 29-Mar-2022	Buy Inter-Se Transfer	1,500,000 @ 0.00 (0.00 %)	Vibha Gagan Sharma

BULK BLOCK DEALS FOR BLISS GVS PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 18-Aug-2023	Buy BULK	1,089,161 @ 91.55	JAINAM SHARE CONSULTANTS PVT. LTD.
BSE 18-Aug-2023	Sell BULK	1,089,161 @ 91.55	M/S. PRARTHANA ENTERPRISES

DIVIDEND BY BLISS GVS PHARMA LIMITED

Ex Dividend Date	Dividend Type	Dividend
18-Jul-2024	DIVIDEND	0.5
12-Jul-2023	DIVIDEND	0.5
20-Jun-2022	DIVIDEND	0.5
13-Sep-2021	DIVIDEND	0.5

SPLIT / BONUS BY BLISS GVS PHARMA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Bliss GVS Pharma Limited

Bliss GVS share price

CONSOLIDATED QUARTERLY RESULT FOR BLISS GVS PHARMA LIMITED

STANDALONE QUARTERLY RESULT FOR BLISS GVS PHARMA LIMITED

CONSOLIDATED ANNUAL RESULT FOR BLISS GVS PHARMA LIMITED

STANDALONE ANNUAL RESULT FOR BLISS GVS PHARMA LIMITED

CONSOLIDATED PROFIT / LOSS FOR BLISS GVS PHARMA LIMITED

STANDALONE PROFIT / LOSS FOR BLISS GVS PHARMA LIMITED

CONSOLIDATED CASH FLOW FOR BLISS GVS PHARMA LIMITED

STANDALONE CASH FLOW FOR BLISS GVS PHARMA LIMITED

CONSOLIDATED BALANCE SHEET FOR BLISS GVS PHARMA LIMITED

STANDALONE BALANCE SHEET FOR BLISS GVS PHARMA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR BLISS GVS PHARMA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR BLISS GVS PHARMA LIMITED

SHARE HOLDING PATTERN FOR BLISS GVS PHARMA LIMITED

PEER COMPARISON FOR BLISS GVS PHARMA LIMITED

CORPORATE ACTIONS FOR BLISS GVS

CORPORATE ANNOUNCEMENTS FOR BLISS GVS

INSIDER TRADING FOR BLISS GVS

BULK BLOCK DEALS FOR BLISS GVS PHARMA LIMITED

DIVIDEND BY BLISS GVS PHARMA LIMITED

SPLIT / BONUS BY BLISS GVS PHARMA LIMITED